Early-Middle Stage Knee Osteoarthritis with
Conditions
Interventions
Control group:Oral celecoxib capsules (200mg po bid) combined with glucosamine (0.75g po bid), with a treatment course of 4 weeks
Experimental group:On the basis of the control group, Ganjuhuangtong Tablets (500mg per tablet) were added, 500mg orally twice a day, for 4 weeks
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Meets the American College of Rheumatology (ACR) classification criteria for primary knee osteoarthritis, grades KL 1-3; 2. Ultrasound examination confirms joint effusion in the affected knee (retropatellar pouch effusion >=5mm); 3. Fully understands the benefits of this study, voluntarily signs the informed consent form, and agrees to cooperate throughout the entire research process.
Exclusion criteria
Exclusion criteria: 1. Have a history of allergy or contraindications to COX-2 inhibitors (celecoxib), glucosamine, ganjuhuangtong, or sulfonamides; 2. Suffer from severe diseases of important organs such as the heart, liver, and kidneys or malignant tumors; 3. Have received treatment for osteoarthritis with glucocorticoids, immunosuppressants, or biological agents within the last 3 months; 4. Have had previous infections, trauma, tumors, or other diseases in the knee joint; 5. Pregnant or lactating women; 6. Patients with mental disorders or those unable to cooperate with the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of fluid accumulation in the knee joint cavity of the affected limb; | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS scores;KOOS scores;Changes in joint mobility;Occurrence of Adverse Reactions; | — |
Countries
China
Contacts
Public ContactSi Haibo
West China Hospital of Sichuan University
Outcome results
None listed